The score was initially developed using clinical and genomic data from 434 patients enrolled in the Short-HER phase III trial15, which randomized individuals with stage I–III HER2+ early breast cancer to receive either 9 weeks or 1 year of adjuvant trastuzumab in combination with multi-agent chemotherapy. This evidence concerns the gene ERBB2 and breast cancer.